Simon Rule, MD, PhD | Authors


Rule Discusses the Potential of Zanubrutinib in the Treatment of Mantle Cell Lymphoma

October 28, 2019

Simon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.

Sequencing Treatment Options in Mantle Cell Lymphoma

July 26, 2019

Simon Rule, MD, PhD, discusses the current treatment approaches for patients with mantle cell lymphoma in both the United Kingdom and the United States. He says treatment strategies are pretty well established on both sides of the Atlantic Ocean.